Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions.

Abstract excerpt

Exogenous enzymes, signaling peptides, and other classes of nonhuman proteins represent a potentially massive but largely untapped pool of biotherapeutic agents. Adapting a foreign protein for therapeutic use poses numerous design challenges. We focus here on one significant problem: modifying the protein to mitigate the immune response mounted against "non-self" proteins, while not adversely affecting the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Design
• Share to Epitopes, T-Lymphocyte